drugset / Trial / NCT04980404
Inqovi Maintenance Therapy in Myeloid Neoplasms
Phase 1
Active not recruiting
22 enrolled
Massachusetts General Hospital
Taiho Oncology, Inc. · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This research is being done to see if the drug Inqov is effective in reducing the chance of myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) relapsing after standard of care stem cell transplant. * This research study involves the study drug Inqovi, which is a combination of the drugs decitabine and cedazuridine.
Timeline
- Start
- 2021-09-17
- Primary completion
- 2023-08-24
- Completion
- 2026-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cedazuridine | Small molecule | — | Oral |
| Subject | Decitabine | Small molecule | — | Oral |